Results 141 to 150 of about 115,106 (246)

Targeting DNA Topoisomerase II in Antifungal Chemotherapy. [PDF]

Molecules, 2022
Kondaka K, Gabriel I.
europepmc   +1 more source

Antibiotic Resistance, Biofilm Genes, and smeDEF Efflux Pump in Clinical Stenotrophomonas maltophilia Isolates From Iran

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Iranian clinical Stenotrophomonas maltophilia isolates showed high susceptibility to trimethoprim/sulfamethoxazole, minocycline, and levofloxacin, but marked resistance to ceftazidime and ticarcillin‐clavulanate, alongside widespread biofilm production and resistance genes.
Haneen Fadhil Jasim, Nisreen Salah Majeed, Asmaa A. Salam, Rania Hameed Hamad, Yeganeh Behrouzi, Erta Rajabi, Razieh Shahbazi   +6 more
wiley   +1 more source

Targeting DNA topoisomerases: past & future

Cancer Drug Resistance, 2021
Gmeiner, William H., van Waardenburg, Robert C. A. M.   +1 more
openaire   +3 more sources

Hydrogels for Cancer Immunotherapy: Strategies From Construction to Application

MedComm, Volume 7, Issue 2, February 2026.
Hydrogels offer an innovative platform for cancer immunotherapy. Through tailorable crosslinking strategies, they form customizable drug delivery platforms that address diverse therapeutic requirements by loading specific immunotherapeutic agents. These systems demonstrate significant clinical potential for precise tumor immunotherapy.
Xiaohua Chen, Shan Wu, Yueyang Zhang, Lilu Feng, Yang Chen, Xuzhao Yang, Ke Men, Jiuqun Zhu, Ming Li   +8 more
wiley   +1 more source

Physiologic and Transcriptomic Effects Triggered by Overexpression of Wild Type and Mutant DNA Topoisomerase I in Streptococcus pneumoniae. [PDF]

Int J Mol Sci, 2023
García-López M, Hernández P, Megias D, Ferrándiz MJ, Campa AG.   +4 more
europepmc   +1 more source

Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background Anthracyclines are among the most effective chemotherapeutic agents used to treat pediatric malignancies. However, their clinical use is limited by dose‐dependent toxicities, particularly cardiotoxicity and secondary malignancies.
Darleen S. Tu, Aaron K. Olson, Kimberly S. Waggie, Nicolas M. Garcia, Virginia J. Hoglund, Stephanie I. Walter, Jenna R. Rosinski, Harini Sadeeshkumar, Radhika Patel, Erolcan Sayar, Michael C. Haffner, Lisa Maves, Jacques Neefjes, Jay F. Sarthy, Elizabeth R. Lawlor, Shireen S. Ganapathi   +15 more
wiley   +1 more source

Transcriptional repression by a secondary DNA binding surface of DNA topoisomerase I safeguards against hypertranscription. [PDF]

Nat Commun, 2023
Lau MS, Hu Z, Zhao X, Tan YS, Liu J, Huang H, Yeo CJ, Leong HF, Grinchuk OV, Chan JK, Yan J, Tee WW.   +11 more
europepmc   +1 more source

Fluoroquinolone‐Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real‐World Data From FAERS (2011–2024)

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
This pharmacovigilance study identifies a wide range of rapid‐onset neuropsychiatric and ocular adverse effects linked to fluoroquinolones (FQ). Disproportionality analysis revealed a disproportionate reporting of suicidal ideation and visual impairment following FQ treatment, emphasizing the urgent need for cautious prescribing and strengthened safety
Hau‐Tak Chau, Ngan Pan Bennett Au
wiley   +1 more source

Molecular Dynamics Investigations of Human DNA-Topoisomerase I Interacting with Novel Dewar Valence Photo-Adducts: Insights into Inhibitory Activity. [PDF]

Int J Mol Sci, 2023
Di Martino J, Arcieri M, Madeddu F, Pieroni M, Carotenuto G, Bottoni P, Botta L, Castrignanò T, Gabellone S, Saladino R.   +9 more
europepmc   +1 more source

Gut Microbiome Dysbiosis is Associated With Human T‐Lymphotropic Virus Type 1 (HTLV‐1) Infection and Disease Progression to HTLV‐1‐Associated Myelopathy/Tropical Spastic Paraparesis: A Cross‐Sectional Study

Smart Medicine, Volume 5, Issue 1, February 2026.
We provide the first comprehensive analysis of changes in the gut bacteriome at different clinical stages of HTLV‐1 infection. HTLV‐1 infection is associated with a dysbiosis that includes reduced bacterial diversity and an inverted Firmicutes/Bacteroidetes ratio.
Lorena Abreu Fernandes, Ana Olivia de Souza, Youko Nukui, Rosa Maria Marcusso, Augusto César Penalva de Oliveira, Jorge Casseb, Patricia Bianca Clissa, Silas G. Villas‐Boas, Sabri Saeed Sanabani   +8 more
wiley   +1 more source